Pharmaceuticals
European Medicines Agency accepts submission of GSK's Marketing Authorisation Application for Zejula (niraparib) in first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
- Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status LONDON, Feb. 27, 2020 /PRNewswire/ -- GlaxoSmithKline plc announced that the European M...
2020-02-27 17:00
1398
Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect
SONGDO, South Korea, Feb. 24, 2020 /PRNewswire/ -- Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations. The company confi...
2020-02-27 15:49
1555
WuXi Diagnostics' integrated testing solution for COVID-19 epidemiological investigation and diagnosis
SHANGHAI, Feb. 27, 2020 /PRNewswire/ -- WuXi Diagnostics has successfully developed a series of COVID-19 detection products, including2019-nCoV IgM Detection kit (Enzyme-linked Immunoassay, ELISA), 2019-nCoV IgM/IgG Detection Kit (Enzyme-linked Immunoassay, ELISA) and 2019-nCoV Nucleic Acid Detec...
2020-02-27 15:47
1919
Clinical Trial of Ganovo® and Ritonavir Combination Therapy on Novel Coronavirus Pneumonia
HANGZHOU and SHAOXING, China, Feb. 27, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the advancement in Novel Coronavirus Pneumonia clinical trial of oral Ganovo® and Ritonavir combination therapy, led by Dr. Hongyi CHEN, the director of the Ninth Hospital ofNanchang...
2020-02-27 08:00
3873
Global Pharmaceutical Contract Manufacturing Organization Market to Reach $102.14 Billion by 2024
Advancements in flexible manufacturing technology to help address new demand in personalized medicine, finds Frost & Sullivan SANTA CLARA, California, Feb. 27, 2020 /PRNewswire/ -- Contract manufacturing organizations (CMOs) are currently transitioning from transactional relationships to strateg...
2020-02-27 01:28
1495
KAHR Medical Raises $18 Million in Private Funding Round
Funds will be used for advancing the Company's next generation immuno-oncology
drug candidates, including lead anti-CD47 product for the treatment of solid
tumors through Phase I/II study in addition to advancing preclinical pipeline
JERUSALEM, Feb. 26, 2020 /PRNewswire/ -- KAHR Medical
2020-02-26 08:30
2827
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
SAN FRANCISCO and SHANGHAI, Feb. 25, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Vir Biotechnology, Inc. ("Vir") (Nasdaq: VI...
2020-02-25 21:30
2845
Connect Biopharma Enhances its Intellectual Property Estate for CBP-307, a Targeted Therapy with Potential in Multiple Autoimmune Diseases, with Patent Issuances in the United States, EU, Japan and Australia
Novel, next-generation S1P1 agonist currently in Phase 2 clinical development for treatment of inflammatory bowel disease SAN DIEGO and TAICANG, China, Feb. 25, 2020 /PRNewswire/ -- Connect Biopharma, a clinical-stage biopharmaceutical company focused on identifying and developing potent and spe...
2020-02-25 21:00
1053
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
STOCKHOLM, Feb. 25, 2020 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced the publication of scientific data on the mechanism of action of cobitolimod, the company's lead drug candidate in development for the treatment of moderate to severe ulcerative colitis. The paper, pu...
2020-02-25 15:26
1280
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China
SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...
2020-02-24 22:00
2426
U.S. FDA accepts GSK's sNDA application for Zejula (niraparib) for first-line maintenance treatment for women with platinum-responsive advanced ovarian cancer
- Submission based on data from the Phase III PRIMA clinical study that demonstrated clinically-meaningful outcomes of niraparib maintenance treatment in the first-line setting regardless of biomarker status - The application is being reviewed under the FDA's Real-Time Oncology Review pilot pr...
2020-02-24 22:00
1330
WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321
SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...
2020-02-24 08:00
6137
Nearly VND 20 billion sponsored by Vingroup for research projects on response to novel coronavirus
HANOI, Vietnam, Feb. 21, 2020 /PRNewswire/ -- 3 units funded by Vingroup
Innovation Foundation (VINIF) include The Company for Vaccine and Biological
Production No.1 (Vabiotech), Pasteur Institute inHo Chi Minh City and Institute
of Preventive Medicine and Public Health.
2020-02-21 10:09
3549
VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update
AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...
2020-02-21 05:10
10107
StoneWise AI-driven Drug Discovery Platform: Investigation and Repurpose of Nucleoside-based RNA Polymerase Inhibitors and Their Potential Use in COVID-19 Infection Treatment
BEIJING, Feb. 20, 2020 /PRNewswire/ -- In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has ...
2020-02-20 20:04
1413
Sihuan Pharmaceutical Announces Acquisition of All Interests and Intellectual Property Rights of Plazomicin, A New Generation of Aminoglycoside Antibiotics in the Greater China Region
HONG KONG, Feb. 20, 2020 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Ltd. (HKEX: 0460, "Sihuan Pharmaceutical" or the "Company", together with its subsidiaries, the "Group") is pleased to announce that Xuanzhu (HK) Biopharmaceutical Limited (''Xuanzhu''), a wholly-owned subsidiary of the...
2020-02-20 18:59
13135
111 Partners with Financial Institutions in Battle Against Coronavirus
SHANGHAI, Feb. 20, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI, "111" or the "Company") has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus (COVID-19) public health crisis, through partnerships with some ofChina's leading financial institution...
2020-02-20 17:00
5341
NeuroVive Pharmaceutical AB Year End Report January - December 2019
STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333 * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroVive compl...
2020-02-19 16:08
6311
VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...
2020-02-19 05:10
10246
Volition Unveils Its Epigenetic Toolbox
AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...
2020-02-18 21:30
8613
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
5608
